Stevanato Group (STVN)
(Delayed Data from NYSE)
$18.44 USD
+0.28 (1.54%)
Updated Jun 12, 2024 04:00 PM ET
After-Market: $18.45 +0.01 (0.05%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth D Momentum C VGM
Brokerage Reports
Stevanato Group S.p.A. [STVN]
Reports for Purchase
Showing records 41 - 60 ( 62 total )
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
In Line 1Q; Orders +29%; Biologic Momentum
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Bioproduction: Catalent''s $350M Indiana Expansion Signals Growth
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
2022 Life Sciences & MedTech Investor Forum
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Far Horizon for Biologic Production and STVN, WST, RGEN, DHR, CTLT
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
31% Discount to European and U.S. Peers Should Narrow
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Omicron: Life Science Tools Firms Likely Seeing Softer Landing
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Lots of Leading Indicators for Future Biological and COVID-19 Vaccine Growth
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Accelerating Industry Capacity Additions Grande for Stevanato; Raise PT to $32
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Life Science Tools: European Perspective Suggests Better Global and Regional Outlook Than US Peers Indicate
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Compelling Bioproduction and Vaccine Trends Within Post-IPO Quarter
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department